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Introduction
The suppressor of cytokine signaling 2 (SOCS2) is a member of the SOCS family of ubiquitin E3 ligases. Members of this family are CIS1 and SOCS1-7 (Yoshimura et al., 2007) . The important features of this family proteins include presence of a SH2 domain and a C-terminal SOCS box. The SOCS box mediates assembly into Elongin B/C-Cullin complexes to facilitate the ubiquitination processes, while the SH2 domain mediates interaction with phosphotyrosine residues. SOCS family proteins are mainly characterized as negative feedback regulators of cytokine receptor signal transduction via the JAK/STAT pathway and have recently been implicated in receptor tyrosine kinase signaling (Bayle et al., 2004; De Sepulveda et al., 1999; . SOCS2 depleted mice displayed high-growth phenotype suggesting a role of SOCS2 in growth control (Horvat and Medrano, 2001 ). SOCS2 interacts with the growth hormone receptor (GHR) through phosphorylated tyrosine residues and negatively regulates receptor signaling (Greenhalgh et al., 2005) . This regulation is mediated through ubiquitination and proteasomal degradation of the receptor .
The type III receptor tyrosine kinase FLT3 is under normal conditions of great importance for the proliferation, survival and differentiation of hematopoietic stem cells and progenitor cells . FLT3 is frequently mutated in acute myeloid leukemia (AML) and the most common mutation is the internal tandem duplication (ITD) in the juxtamembrane domain (Levis and Small, 2003) .
This mutation leads to ligand-independent activation of receptor as well as downstream signaling. The signaling mediated by activated FLT3 is tightly regulated by adaptor proteins. For example, interaction with SOCS6 and Lnk (Lin et al., 2012) negatively regulates downstream signaling while association with Grb2 ), Grb10 (Kazi and Ronnstrand, 2012a) or SLAP (Kazi and Ronnstrand, 2012b) results in activation of downstream signaling.
Here we present evidence that SOCS2 interacts with both normal and oncogenic FLT3. This association is mediated through phosphotyrosine residues 589 and 919 of FLT3. SOCS2 co-localizes with FLT3 in Ba/F3 cells and increases receptor ubiquitination followed by degradation in the proteasomes.
Furthermore SOCS2 expression suppresses Erk 1/2 and STAT5 signaling. SOCS2 expression inhibits FLT3-ITD-mediate colony formation in semi-solid culture.
Materials and methods

Reagents and antibodies
Rabbit polyclonal anti-SOCS2 serum was raised and purified as described before (Blume-Jensen et al., 1993) . The 4G10 and ubiquitin antibodies were from Millipore and Covance Research Products, respectively. The anti-FLT3 antibody was described previously (Razumovskaya et al., 2009 ).
Phycoerythrin (PE)-conjugated FLT3 antibody was from BD Biosciences. The anti-phospho-Akt and other antibodies were from Epitomics and Santa Cruz Biotechnology, respectively. The RbX antiphosphoserine antibody was from Millipore.
Expression constructs
The pcDNA3-FLT3-WT, pcDNA3-FLT3-ITD, pMSCV-FLT3-WT and pMSCV-FLT3-ITD constructs were described previously (Razumovskaya et al., 2009) . The pCMV5-Myc-FLAG-SOCS2-WT plasmid was purchased from OriGene. The pcDNA3-SOCS2-SH2-FLAG plasmid was generated by subcloning FLAG-tagged SOCS2-SH2 domain into the pcDNA3 vector.
Cell culture, transient and stable transfection
The COS-1 cells (cultured in Dulbecco's modified Eagle's medium supplemented with 10% FBS) were transiently transfected using JetPEI (Polyplus-transfection) according to the manufacturer's instructions. Ba/F3 cells were cultured in RPMI 1640 medium supplemented with 10% heat inactivated FBS and 10 ng/ml recombinant murine interleukin-3 (IL-3). Ba/F3-FLT3-WT and Ba/F3-FLT3-ITD cells were generated using retroviral transduction as described before . Cells were further transfected with pCMV5-Myc-FLAG-SOCS2-WT construct using 4D-nucleofector system (Lonza) followed by two weeks selection with 0.8 mg/ml G-418. Expression of FLT3 was verified by flow cytometry and Western blotting, while SOCS2 expression was checked by Western blotting. Ba/F3-FLT3-WT cells were cultured in same medium used for Ba/F3 and Ba/F3-FLT3-ITD, Kasumi-1, THP-1, MV4-11 and MOLM-13 cells were cultured in RPMI 1640 medium supplemented with 10% heat inactivated FBS. P815 cells were cultured in the same medium as was used for COS-1 cells.
Immunoprecipitation and Western blotting
The COS-1 cells were serum-starved overnight 6 hours after transfection and then stimulated at 37°C for the indicated time with 100 ng/ml of FL (Prospec Tany). On the other hand Ba/F3 cells were serum-starved four hours in RPMI-1640 medium and then stimulated with 100 ng/ml of FLT3 ligand (FL) at 37°C for five minutes. Cells were then processed for immunoprecipitation and Western blotting as described previously Voytyuk et al., 2003) .
Affinity fishing of SOCS2 with immobilized peptides
Peptides corresponding to the tyrosine motifs of FLT3 intracellular domain either phosphorylated or not were used for affinity fishing (for sequence see Lin et al., 2012) ). Peptides were immobilized to UltraLink beads (Thermo Scientific) according to the manufacturer's instructions. The SOCS2 construct was transfected into the COS-1 cells. Twenty four hours after transfection cells were lysed and 50 µl of peptide slurry was added to each ml of cell lysates. Then proteins pulled down by peptide were processed for Western blotting.
Analysis of SOCS2 expression in patient samples
The SOCS2 expression was retrieved from microarray dataset for human patient samples from different cancers (GSE9476, GSE5550, GSE5788, GSE4290, GSE2223, GSE20437, GSE6691, GSE4115, GSE6919 and GSE8671) available through the NCBI GEO site.
Co-localization study
Ba/F3-FLT3-WT-SOCS2-FLAG cells were after starvation stimulated or not with FL for 5 minutes. Cells were then fixed with 4% paraformaldehyde and permeabilized with 0.5% Triton-X 100.
After blocking with goat serum cells were stained with fluorophore-conjugated anti-FLT3 and anti-FLAG antibodies as well as with DAPI. Cellular localization of FLT3 and SOCS2 was analyzed by a Carl Zeiss LSM 710 Laser Scanning Microscope. Co-localization was measured with CoLocalizer Pro 2.7.1 software.
Colony formation and cell proliferation assay
Ba/F3-FLT3-ITD cells transfected with SOCS2 or empty control vector were cultured in semisolid methylcellulose medium (MethoCult M3231, Stem Cell Technologies) for 5 days. Cell proliferation was performed using PrestoBlue cell viability assays (for detailed method see ).
Result
SOCS2-SH2 domain display closest structural homology to the SOCS6-SH2 domain
Recently we reported that SOCS6 is overexpressed in AML . To understand the role of other SOCS family members in AML, we compared mRNA expression from micro-array data of AML patient samples with that of healthy donors. We observed that expression of SOCS2, SOCS5 and SOCS6 was upregulated in AML (Fig. 1A) . In the same report we also provided evidence that SOCS6 associates with FLT3 and negatively regulates FLT3 downstream signaling . Since expressions of SOCS2 and SOCS5 are also deregulated in AML and FLT3 is frequently mutated in this disease, we hypothesized that similar to SOCS6, SOCS2 or SOCS5 might also play a role in FLT3 signaling. SOCS6 associates with FLT3 through FLT3-pY residues and the SOCS6-SH2 domain ). Thus we initially compared SH2 domains of SOCS proteins using protein sequences. We observed that SOCS-SH2 domains are divided into four subgroups (Fig. 1B) . Although critical arginine residues are conserved within the family neither SOCS2 nor SOCS5 displayed a close homology with SOCS6 ( Fig. 1C ) and thus we were unable to make a conclusion whether SOCS2 or SOCS5 has a probability to interact with FLT3 from sequence alignment.
Then we compared 3D-structure of SOCS2-SH2 and SOCS5-SH2 domain with that of SOCS6-SH2 domain. We aligned SOCS2-SH2-SOCS6-SH2 and SOCS5-SH2-SOCS6-SH2 domain pairs using SPalign. The SOCS2-SH2 domain displayed closer structural similarity (RMSD-1.7Å) than SOCS5-SH2 (RMSD-1.9Å) with SOCS6-SH2 ( Fig. 1F and 1G ). The binding site of the phosphotyrosine moiety is known to be created by two arginine and one serine residues shown in figure 1D and 1E (Bullock et al., 2006; Zadjali et al., 2011) . Although all three residues in SOCS2-SH2 domain completely showed similar orientation ( Fig. 1F) , the arginine residue in SOCS5-SH2 domain corresponding to SOCS6-R432 displayed different orientation (Fig. 1G ). Thus we suggest that SOCS2, but not SOCS5, has a higher probability to interact with FLT3.
SOCS2 expresses in AML
We then compared SOCS2 expression in 11 different cancers with corresponding normal tissues using micro-array data. We observed that SOCS2 expression was upregulated in AML, glioblastoma and myeloma patients ( Fig. 2A ). This observation was further supported by the data that SOCS2 protein expression was upregulated in the AML cell lines Kasumi-1, THP-1, MV4-11 and MOLM-13 as compared to mastocytoma cell line P815 (Fig. 2B) . SOCS2 expression did not show any significant difference between different sexes or between patient groups that had complete remission or relapsed ( Fig.   2C ), but it showed a weak correlation (r 2 =0.246) with the age of AML patients (Fig. 2D) . Furthermore, SOCS2 expression was not significantly altered in different AML subtypes (Fig. 2E ) and also did not show any correlation with overall survival (Fig. 2F ). We showed in our previous report that SOCS6 expression was elevated in response to FLT3 ligand (FL) stimulation and also in patients expressing FLT3-ITD mutant ). Thus we analyzed whether SOCS2 expression was also elevated in patients carrying FLT3-ITD mutation. We observed that similar to SOCS6, SOCS2 expression was significantly upregulated in patients having FLT3-ITD mutation (Fig. 2G ). This observation was also supported by the recent study that SOCS2 expression was significantly elevated in cell lines as well as murine bone marrow cells expressing FLT3-ITD (Reddy et al., 2012) .
SOCS2 interacts with FLT3 through SOCS2-SH2 domain
Since we observed that SOCS6 associates with FLT3 in a phosphorylation dependent manner , we tested whether SOCS2 also associates with the receptor tyrosine kinase FLT3.
SOCS2 associates with FLT3 in response to FL stimulation in THP-1 and MOLM-13 cell lines (which express FLT3-WT), while it constitutively interacts with FLT3 in the MV4-11 cell line that expresses FLT3-ITD (Fig. 3A) . Moreover, by co-transfecting COS-1 cells with SOCS2-FLAG and FLT3-WT or FLT3-ITD we further provide evidence that SOCS2 interacts with both FLT3-WT and FLT3-ITD (Fig.   3B ). Using the SOCS2-SH2 domain we further showed that this interaction is mediated through SOCS2-SH2 domain (Fig. 3C ). Since SH2 domain interacts with phosphotyrosine residue we aimed to detect the phosphotyrosine residues in FLT3 which are required for SOCS2 interaction. Using 12 phospho-peptides corresponding to different tyrosine phosphorylation sites in FLT3, we identified tyrosine 589 and 919 residues as binding sites for SOCS2 (Fig. 3D) .
FL-stimulation induces SOCS2 tyrosine and serine phosphorylation
FLT3 activation induces tyrosine phosphorylation of SOCS6 ). Thus we analyzed whether FLT3 activation also initiates SOCS2 tyrosine phosphorylation. We transfected COS-1 cells with FLT3-WT and SOCS2-FLAG constructs and after overnight starvation cells were stimulated with FL for different periods of time. FL-stimulation initiated SOCS2 tyrosine phosphorylation in FLT3
transfected cells (Fig. 4A ). In addition we observed that SOCS2 remains serine phosphorylated in COS-1 cells and FL-stimulation potentiates SOCS2 serine phosphorylation (Fig. 4B ). Although association with certain adaptor proteins, such as Lnk, regulates the receptor tyrosine phosphorylation (Lin et al., 2012) , an increased SOCS2 expression did not alter FLT3 tyrosine phosphorylation (Fig. 4C) .
SOCS2 co-localizes with FLT3 in the cell membrane
We generated Ba/F3-FLT3-WT-Empty vector and Ba/F3-FLT3-WT-SOCS2-FLAG cell lines to test the role of SOCS2 in hematopoietic cells. FLT3 and SOCS2 proteins levels were verified by flow cytometry (Fig. 5A ) and Western blotting (Fig. 5B ). Initially we investigated the subcellular localization of SOCS2 protein in Ba/F3 cells. Cells were stimulated with FL for 5 minutes after starvation and fixed for immunostaining. Fluorophore-conjugated anti-FLAG and anti-FLT3 antibodies were used to detect localization of SOCS2 and FLT3 respectively. SOCS2 was found to be localized mainly in the cytosol and plasma membrane (Fig. 5C ). SOCS2 and FLT3 co-localization was also observed in Ba/F3 cells which further increased significantly in response to FL-stimulation ( Fig. 5C and 5D ).
SOCS2 increases ubiquitination of the FLT3 receptor
Since SOCS2 exhibits ubiquitin ligase activity , we tested FLT3-ubiquitination in SOCS2 expressing cells. After stimulation of transfected Ba/F3 cells with FL for different time points, we observed that FLT3-ubiquitination was increased in cells transfected with SOCS2 while FLT3 tyrosine phosphorylation remained unchanged (Fig. 6A) . The difference in receptor ubiquitination was evident by statistical analysis of multiple experiments at the 5 minute time point (Fig   6B) .
SOCS2 increases degradation of FLT3 in proteasome
Receptor ubiquitination leads to degradation of receptor. Thus we tested whether SOCS2 plays a role in FLT3 degradation. We observed that SOCS2 expression significantly increased receptor degradation in Ba/F3 cells (Fig. 7A) . Ubiquitin ligases are known to direct the receptor degradation either to proteasomes or to the lysosomes. Using selective proteasome and lysosome specific inhibitors we tested which pathway is initiated by SOCS2. The proteasome inhibitor MG132 but not lysosome inhibitor chloroquine diphosphate inhibited SOCS2-mediated FLT3 degradation (Fig. 7B ).
SOCS2 selectively regulates Erk signaling
FLT3 activation leads to activation of several downstream signaling pathways. Major pathways include the PI3K-Akt pathway and the Ras/Erk pathway . To understand the effect of SOCS2 on FLT3 downstream signaling we tested Akt and Erk 1/2 activation following FLstimulation using phospho-specific antibodies. Ba/F3-FLT3 cells expressing SOCS2 displayed decreased Erk 1/2 phosphorylation without affecting Akt phosphorylation (Fig. 8A ). This effect was observed after 5 minute of receptor activation (Fig. 8B) . Thus, since the effect is selective for Erk phosphorylation, it cannot be fully explained by increased degradation of FLT3.
SOCS2 negatively regulates FLT3-ITD-mediated STAT5 phosphorylation
SOCS2 is a negative regulator of JAK2/STAT5 signaling (Quentmeier et al., 2008) . Since only (Fig. 9A ) and SOCS2 expression was determined by Western blotting (Fig. 9B ). SOCS2 expression led to a significant decrease of FLT3-ITD-mediated STAT5 phosphorylation in the Ba/F3 cells (Fig. 9C) .
SOCS2 negatively regulates FLT3-ITD-mediated cell proliferation and colony formation in semi-solid culture
To elucidate the biological outcome of SOCS2 expression in Ba/F3 cells we tested FLT3-ITDmediated cell proliferation and colony formation potential in semi-solid culture. SOCS2 expression significantly decreased FLT3-ITD mediated cell prolideration (Fig. 10A) . Furthermore, SOCS2
expression led to reduced size of colonies of Ba/F3-FLT3-ITD cells (Fig. 10B) . The Ba/F3-FLT3-ITD cells expressing SOCS2 displayed significantly reduced number of colonies in semi-solid culture (Fig.   10C ).
Discussion
Signaling through receptor tyrosine kinases is tightly regulated. Protein kinases, phosphatases and ubiquitin ligases play critical roles in this regulation. This report suggests a mechanism of FLT3 regulation by the SOCS2 ubiquitin ligase. SOCS2 associates with FLT3 through phosphotyrosine residues 589 and 919 in FLT3 and this interaction increases FLT3 ubiquitination which is followed by degradation of the receptor as well as a decrease in Erk 1/2 and STAT5 phosphorylation. Thus SOCS2 exhibits a negative role on FLT3 signaling.
SOCS2 binding to wild-type FLT3 was found to be dependent on ligand stimulated phosphorylation of Y 589 and pY 919 . The phosphorylated residue pY 589 is located in the juxtamembrane domain of FLT and has previously been shown to be of importance for activation of Src family kinases (SFKs) (Heiss et al., 2006) . Thus, there is likely to be a competition between SOCS2 and SFKs for binding to this site, which might explain some of the effects on signaling. The role of the phosphorylated residue pY 919 has not been studied in detail. In the related receptor c-Kit the corresponding site pY900 was found to mediate recruitment of the adapter protein Crk through the p85 subunit of PI3-kinase . In the PDGF -receptor the corresponding site, pY934, is involved in regulating the activity of PLC-   . Recently we showed that SOCS6 and the adapter protein Lnk interact with FLT3 through pY 919 and thereby negatively regulate the receptor signaling Lin et al., 2012) . Thus the pY 919 residue seems to be the site in FLT3 which interacts with several negative regulators of signaling.
SOCS2 constitutively interacts with FLT3-ITD and is predominantly localized to the cell membrane indicating that oncogenic FLT3 signaling might also be partially regulated by SOCS2 and this regulation takes place when receptor localizes to the cell membrane. Similar to SOCS6 FLT3 ligand induces SOCS2 tyrosine phosphorylation. In addition, SOCS2 remains serine phosphorylated in unstimulated COS-1 cells and FLT3 activation potentiates this event. The exact biological role of SOCS2
phosphorylations is yet to be defined. SOCS2 shares serine residue in SOCS-box with S144 of Vif proteins (Mehle et al., 2004) . Phosphorylation of S114 of Vif led to a decrease of Elongin C binding without altering ability of substrate degradation. Phosphorylation of SOCS1 by PIM serine threonine kinases stabilizes SOCS1 thus inhibiting STAT6 tyrosine phosphorylation (Chen et al., 2002) . Tyrosine phosphorylated SOCS3 displays impaired binding with Elongin C (Haan et al., 2003) , but strongly inhibits STAT5 activation (Cacalano et al., 2001) . These findings suggests that phosphorylation events regulates stability of SOCS proteins and potentiates its ability of STAT pathways inhibition.
SOCS2 increases ligand-induced ubiquitination and accelerates degradation of FLT3 which is in
line with the observations that SOCS2 regulates the stability of interacting proteins by recruiting the ubiquitination machinery (McBerry et al., 2012; Vesterlund et al., 2011) . SOCS2-mediated receptor degradation was blocked by MG132 but not by chloroquine suggesting that SOCS2 promotes FLT3 degradation through proteasomes but not through the lysosomes which was also observed with GHR .
SOCS2 also regulates receptor downstream signaling and displays a degree of specificity in regulation of receptor downstream signaling. Since SOCS2 has the ability to induce receptor degradation, it is expected that SOCS2 expression could negatively regulate downstream signaling. However, to our surprise we found that SOCS2 selectively regulates Erk signaling without affecting the Akt pathway. This
is similar to what we previously have found regarding SOCS6 and FLT3 signaling .
Thus, the reduced activation of Erk can't solely be explained by degradation of FLT3 since that would also have affected Akt phosphorylation.
The STAT5 activation by FLT3-ITD is supposed to take place in the endoplasmic reticulum (ER) (Schmidt-Arras et al., 2009) and it is known that ligand stimulation does not induce STAT5 activation in cells expressing FLT3-WT (Spiekermann et al., 2003) . The observation that STAT5 phosphorylation is blocked by SOCS2 expression suggests that constitutive FLT3-ITD-SOCS2 association disrupts STAT5 phosphorylation mediated by FLT3-ITD. SOCS2 expression partially blocked FLT3-ITD-mediated colony formation which further provides evidence that SOCS2 blocks FLT3-ITD oncogenic signaling by blocking phosphorylation STAT5, an event known to be essential for FLT3-ITD-mediated transformation.
SOCS2 mRNA expression is regulated by STAT5 (Sen et al., 2012) and we observed that SOCS2 mRNA expression is upregulated in cells expressing oncogenic FLT3. Since oncogenic FLT3 directly activates STAT5, we suggest that elevated SOCS2 expression is mediated through STAT5 activation by oncogenic FLT3 that further regulates FLT3 signaling (Fig. 11) . Thus we suggest that SOCS2 negatively regulates FLT3 signaling by direct interaction and thereby induces receptor ubiquitination and its degradation.
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Authors declare no conflict of interest. blotting. Signal intensities from multiple experiments were quantified using multi-gauge software to calculate the receptor degradation. ***, p<0.001; *, p<0.05; ns, not significant. (A) Ba/F3-FLT3-WT-empty vector or Ba/F3-FLT3-WT-SOCS2-FLAG cells were treated with 100 ng/ml of FL for different time points before lysis. Total cell lysates were analyzed by western blotting using phospho-specific antibodies. (B) Blots from multiple experiments were quantified using multigauge software to calculate the inhibition. ***, p<0.001; *, p<0.05; ns, not significant. antibody followed by Western blotting analysis using 4G10 and STAT5 antibodies. Blots from multiple experiments were quantified using multi-gauge software to calculate the inhibition. **, p<0.01. Oncogenic FLT3 activates STAT5 leading to nuclear translocation and expression of SOCS2 that associates with tyrosine phosphorylated FLT3 and directs receptor to ubiquitination and degradation. This events further inhibits Erk1/2 and STAT5 activation.
Figure legends
